# Subacute Cutaneous Lupus Erythematosus Secondary to Intravenous Immunoglobulin Infusions

## TL;DR

This paper reports a rare case of a skin condition called subacute cutaneous lupus that developed after a patient received IVIG treatment for a nerve disorder.

## Contribution

The paper highlights a rare side effect of IVIG treatment, linking it to the development of subacute cutaneous lupus.

## Key findings

- A case of subacute cutaneous lupus erythematosus occurred during IVIG treatment for CIDP.
- IVIG is rarely associated with the development of this skin condition.
- Healthcare providers should be aware of this rare adverse effect when prescribing IVIG.

## Abstract

Subacute cutaneous lupus erythematosus (SCLE) is a variant of cutaneous lupus erythematosus (CLE) characterized by distinct skin lesions. Clinical manifestations typically include annular or psoriasiform skin lesions, often localized in sun-exposed areas such as the chest and back. The pathogenesis of SCLE is largely unknown, and contributing factors include genetics, environmental exposures, and immunological dysregulation. SCLE may be idiopathic or drug-induced, with common triggers being calcium channel blockers, thiazide diuretics, and terbinafine. Intravenous immunoglobulin (IVIG) treatment, frequently used in various autoimmune conditions, has a rare association with SCLE. We report a case in which this condition arose during IVIG treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). Knowledge of this rare effect is beneficial to all providers who prescribe IVIG, including neurology, rheumatology, and dermatology.